Figure 4 | Scientific Reports

Figure 4

From: miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met

Figure 4

miR-19a decreases c-Met expression and blocks its downstream pathway (A,B). Down-regulating miR-19a increased the c-Met protein and mRNA levels. Pc9 cells were treated with gefitinib (0.1 μM) and then transfected with Inh-19a or Inh-NC, after 48 h, c-Met protein (A) and mRNA (B) level were detected; (C,D) overexpressing miR-19a reduced c-Met protein and mRNA level. Pc9 GR cells were treated with gefitinib (1 μM) and then trasfected with miR-19a or miR-NC, c-Met protein (C) and mRNA (D) level were detected after 48 h; (E) miR-19a overexpression blocks the c-Met downstream pathway. Pc9 GR cells were treated with gefitinib (1 μM) and then transfected with miR-19a or miR-NC, and p-Akt and p-Erk levels were measured after 48 h; (F) Down-regulating miR-19a activated the c-Met downstream pathway. Pc9 cells were treated with gefitinib (0.1 μM) and then transfected with Inh-19a or Inh-NC, and the p-Akt and p-Erk levels were measured after 48 h.

Back to article page